Immunotech-B (01541.HK) was increased by 50,000 shares purchased by Chairman Tian Wenzhi.

According to the latest disclosure of equity interests from the Stock Exchange, on May 13, 2026, Yimengangke-B (01541.HK) was increased by Tian Wenzhi, the chairman, chief executive officer, and executive director, who purchased 50,000 shares at an average price of HKD 3.87 per share, involving approximately HKD 193,500. After the increase, Tian Wenzhi's total number of shares held reached 116,184,090, with the shareholding percentage rising from 26.91% to 27.63%.

Gelonghui FinanceMay 14 21:43

ImmuneOnco Sets 2026 AGM to Approve Results, Profit Plan and Share Issuance Mandate

TipRanksApr 30 17:16

IMMUNEONCO-B: Annual Report 2025

HKEXApr 29 06:11 · Announcements

Immunotech Biopharmaceuticals has risen, with its subsidiary Immunocare completing the enrollment of all subjects for the MAD study of the IMC-003 project.

IMMUNOON-B (01541) once surged over 5%. As of the time of writing, it has risen by 5.29%, trading at HKD 5.77, with a turnover of HKD 8.9842 million.

Zhitong FinanceApr 22 14:47

Hong Kong Stock Market Midday Review | Hang Seng Index fell 1.18% in the morning session, while storage-related concept stocks performed strongly against the market trend.

51 Vision (06651) surged over 11% after the company recently unveiled the world's first 'physical intuition' world model.

Zhitong FinanceApr 13 12:00

Stock Movement in Hong Kong | Yiming Angke-B (01541) Surges Over 17% as CD47 Bispecific Antibody Clinical Value is Supported by Science Magazine

Yimeng Angke-B (01541) surged over 17%. As of the time of writing, it had risen by 17.09%, trading at HKD 5.55, with a turnover of HKD 11.4379 million.

Zhitong FinanceApr 13 10:21